Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Total Current Liabilities: 2019-2025

Historic Total Current Liabilities for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $223.4 million.

  • Harmony Biosciences Holdings' Total Current Liabilities rose 38.52% to $223.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $223.4 million, marking a year-over-year increase of 38.52%. This contributed to the annual value of $175.1 million for FY2024, which is 6.90% up from last year.
  • Latest data reveals that Harmony Biosciences Holdings reported Total Current Liabilities of $223.4 million as of Q3 2025, which was up 24.02% from $180.1 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' Total Current Liabilities' 5-year high stood at $223.4 million during Q3 2025, with a 5-year trough of $33.4 million in Q1 2021.
  • For the 3-year period, Harmony Biosciences Holdings' Total Current Liabilities averaged around $151.9 million, with its median value being $161.3 million (2024).
  • In the last 5 years, Harmony Biosciences Holdings' Total Current Liabilities tumbled by 60.03% in 2021 and then soared by 125.43% in 2022.
  • Over the past 5 years, Harmony Biosciences Holdings' Total Current Liabilities (Quarterly) stood at $53.8 million in 2021, then spiked by 46.69% to $78.9 million in 2022, then surged by 107.62% to $163.8 million in 2023, then climbed by 6.90% to $175.1 million in 2024, then skyrocketed by 38.52% to $223.4 million in 2025.
  • Its last three reported values are $223.4 million in Q3 2025, $180.1 million for Q2 2025, and $175.1 million during Q1 2025.